Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies — Pieter Sonneveld (2023) | RDL Network
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Article 2023 en
Authors
PS
Pieter Sonneveld
PR
Paul G. Richardson
HL
Heinz Ludwig
Abstract
1 min read
These analyses demonstrate a consistent benefit for melflufen and dexamethasone in patients with relapsed/refractory multiple myeloma who have not received an ASCT or progressed >36 months after receiving an ASCT (ClinicalTrials.gov identifier: NCT03151811).
Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Meletios A Dimopoulos, Jesús F. San Miguel, Andrew R. Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kım, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis,
Paul G. Richardson, Aurore Perrot, Jesús F. San Miguel, Meral Beksaç, Ivan Špıčka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Shang‐Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Rick Zhang, Franck Dubin, Mony Morisse, Kenneth C. Anderson
Discussion(0)
No comments yet. Be the first to comment.